АНДРОГЕНДЕПРИВАЦИОННАЯ ТЕРАПИЯ АНТАГОНИСТАМИ ЛГРГ ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: ЛУЧШИЙ КОНТРОЛЬ НАД ЗАБОЛЕВАНИЕМ ПРИ МЕНЬШЕМ РИСКЕ ПОБОЧНЫХ ЭФФЕКТОВ. РЕЗУЛЬТАТЫ АНАЛИЗА 6 СРАВНИТЕЛЬНЫХ РАНДОМИЗИРОВАННЫХ ИССЛЕДОВАНИЙ III ФАЗЫ ДЕГАРЕЛИКСА И АГОНИСТОВ ЛГРГ

Андрогендепривационная терапия антагонистами лютеинизирующего гормона рилизинггормона (ЛГРГ) по сравнению с терапией агонистами этого гормона обеспечивает лучший контроль над заболеванием за счет более быстрой и стойкой супрессии уровня тестостерона без эффекта «вспышки» и не требует превентивного назначения антиандрогенов. Антагонист ЛГРГ 3-го поколения  –  дегареликс  –  характеризуется  хорошей  переносимостью  и  не  вызывает  системных  аллергических  реакций, свойственных для ранее известных препаратов этой группы. Как было показано, применение дегареликса характеризовалось бо-лее длительным ответом, оцениваемым по простатспецифическому антигену, при меньшем риске побочных эффектов, а именно серьезных кардиоваскулярных и костных осложнений, инфекций мочевых путей (ИМП). Так, у мужчин с сердечно-сосудистыми заболеваниями в анамнезе риск развития серьезных сердечно-сосудистых осложнений или смерти снижался на 56 % уже в тече-ние первого года терапии дегареликсом. Полученные данные позволяют рассматривать дегареликс как препарат выбора для первой линии гормональной терапии больных распространенным РПЖ, особенно у мужчин с сердечно-сосудистой патологией, высоким риском ИМП и костных осложнений.

1. Heidenreich A., Bastian P. J., Bellmunt J. et al. EAU Guidelines 2013; p. 1–154.

2. Payne H., Mason M. Androgen deprivation therapy as adjuvant / neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011;105:1628–34.

3. Sharifi N., Gulley J. L., Dahut W. L. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17: 305–15.

4. Gittelman M., Pommerville P. J., Persson B. E. et al. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 2008;180:1986–92.

5. Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–8.

6. Van Poppel H., Tombal B., de la Rosette J. L. еt al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805–13.

7. Koechling W., Hjortkjaer R., Tankу L. B. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 2010;70:580–7.

8. Bhasin S., Berman N., Swerdloff R. S. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl 1994;15:386–91.

9. Varenhorst E., Wallentin L., Carlstrцm K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol 1982;16:31–6.

10. Ben-Josef E., Yang S. Y., Ji T. H. et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970–6.

11. Mariani S., Salvatori L., Basciani S. et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175:2072–7.

12. Radu A., Pichon C., Camparo P. et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621–30.

13. Canon J. G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokin 2011;53:141–4.

14. Tombal B., Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 2008;7:15–21.

15. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005;4:14–9.

16. Perachino M., Cavalli V., Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105:648–51.

17. Miller K., Crawford D., Shore N. et al. Disease control-related outcomes from an analysis of six comparative randomized сlinical trials of degarelix versus luteinising hormone-releasing hormone (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 678.

18. Tombal B., Miller K., Boccon-Gibod L. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836–2.

19. Tombal B., Albertsen P., de la Taille A. et al. Lower risk of cardiovascular (CV) events and death in men receiving ADTby gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 677.

20. Albertsen P. C., Klotz L., Tombal B. et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. Eur Urol 2014;65:565–73.

21. Axcrona K., Aaltomaa S., da Silva C. M. et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 2012;110 (11):1721–8.

22. Mason M., Maldonado Pijoan X., Steidle C. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus gosere-lin plus bicalutamide. Clin Oncol (R Coll Ra-diol) 2013;25 (3):190–6.

23. Albertsen P. C., Moore D. F., Shih W. et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29 (10):1335–41.

24. Conteduca V., DiLorenzo G., Tartaron A., Aita M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer. An unresolved controversy. Crit Rev Oncol Hematol 2013;86:42–51.

25. Shahani S., Braga-Basaria M., Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042–9.

26. Smith M. R., Finkelstein J. S., McGovern F. J. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87 (2):599–603.

27. Smith M. R., Lee H., Nathan D. M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305–8.

28. Stanworth R. D., Jones T. H. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;37:74–90.

29. D’Amico A. V., Denham J. W., Crook J. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–5.

30. Keating N. L., O’Malley A. J., Freedland S. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39–43.

31. Keating N. L., O’Malley A. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24: 4448–56.

32. Levine G. N., D’Amico A. V., Berger P. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833–40.

33. Saigal C. S., Gore J. L., Krupski T. L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493–500.

34. Tsai H. K., D’Amico A. V., Sadetsky N. et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Institute 2007;99:1516–24.

35. Alibhai S. M., Duong-Hua M., Sutradhar R. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 7:3452–58.

36. Roach M., Bae K., Speight J. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–91.

37. Studer U. E., Whelan P., Albrecht W. et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868–76.

38. Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84 (2):743–50.

39. Andersson J., Libby P., Hansson G. K. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134 (1):33–46.